Jennifer Gershman, PharmD, CPh

September 02, 2021

Tecentriq and Keytruda may also be eventually approved as adjuvant therapies.

September 01, 2021

Developers of the drug express disappointment but plan to seek meetings with regulators in hopes of reviving the application.

August 13, 2021

The confirmatory trial of one of the approved drugs, Pepaxto, was halted when data suggested it was associated with a higher mortality rate.

August 12, 2021

At this time, two of three conferences have been reverted to a in-person and virtual format. This includes The American Urological Association (AUA) 2021 Annual Meeting and the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.

August 10, 2021

NCCN adds Rylaze to guidelines soon after was approved by the FDA and a British company reports positive results for its CAR-T therapy.

August 03, 2021

The Society for Immunotherapy of Cancer (SITC) released guidelines based on FDA approved immune checkpoint inhibitors (ICIs) for the treatment of urothelial cancer arising from the bladder and other areas of the urinary tract. The guidelines were based around therapies such as the programmed cell death protein 1 (PD-1) inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) and the programmed cell death ligand 1 (PD-L1) inhibitors, Tecentriq (atezolizumab), Bavencio (avelumab) and Imfinzi (durvalumab).